Liyuan C. Zhang
1055 Sanxiang Road
Suzhou, 215004, China
Suzhou, 215004, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Barrier-matched, pharmacodynamic (PD)-gated immunotherapy development in MSS/pMMR colorectal cancer.
Barrier-matched, pharmacodynamic (PD)-gated immunotherapy development in MSS/pMMR colorectal cancer.
Journal: Critical reviews in oncology/hematology
Published: May 22, 2026
Citraconate preserves T cell stemness and antitumor immunity.
Journal: Science immunology
Published: May 01, 2026
Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).
Journal: Technology in cancer research & treatment
Published: March 13, 2026
Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol).
Journal: Translational lung cancer research
Published: February 14, 2026
Efficacy and safety of combined RANKL and PD-1 inhibitors in bone metastases: a retrospective study.
Efficacy and safety of combined RANKL and PD-1 inhibitors in bone metastases: a retrospective study.
Journal: Translational cancer research
Published: February 08, 2026
Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).
Journal: Technology in cancer research & treatment
Published: November 27, 2025
Safety and efficacy of PRaG therapy in elderly cancer patients.
Journal: Immunotherapy advances
Published: November 19, 2025
A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.
Journal: Technology in cancer research & treatment
Published: November 18, 2025
Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors.
Journal: Clinical and experimental immunology
Published: August 10, 2025
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer.
Journal: Cancer management and research
Published: July 24, 2025
ARHGAP11A, a member of Rho GTPase activating protein family, as a prognostic biomarker linked to DNA damage response across pan-cancer.
Journal: BMC cancer
Published: June 23, 2025
Clinical Considerations of Splenic Dose Constraints to Mitigate Radiation-Induced Lymphopenia.
Journal: Cancer medicine
Published: June 07, 2025
Last Updated: 09/26/2026